HIF1A and atherosclerosis: Despite the observed dichotomy in the role of HIF-1 in experimental atherosclerosis, both genetic and pharmacological inhibition of prolyl hydroxylase domain enzymes (PHD) have shown its ability to inhibit atherosclerosis development in high-fat-diet-fed LDL receptor-deficient mice (Figure 5) [80].